StockNews.AI
VERO
StockNews.AI
134 days

Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

1. VERO to release Q1 2025 financial results on May 15. 2. Conference call scheduled for discussing results at 8:00 a.m. ET. 3. Company engaged in global medical aesthetic technology markets. 4. Investors include notable healthcare equity firms. 5. Product portfolio comprises advanced aesthetic and hair restoration devices.

Earnings
+28.39%Current Return
VS
+0.14%S&P 500
$2.3604/07 07:35 AM EDTEvent Start
$3.0304/08 01:58 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Scheduled financial results often increase investor interest. Strong quarterly performance past examples show possible price upticks.

How important is it?

Upcoming earnings are crucial for investor confidence. Historical results can significantly influence stock valuation.

Why Short Term?

The May result announcement is imminent, expected to affect immediate market perceptions significantly.

Related Companies

HEARAXGNMGTA
TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com. For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13753054. The webcast will be archived at ir.venusconcept.com. About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.

Related News